Diagnosing eye illnesses requires cumbersome machines and specialist clinics, which are sometimes concentrated in massive cities. However for hundreds of thousands residing in smaller cities and rural areas, entry to well timed eye screening stays restricted.
Bengaluru-based healthtech startup Remidio is making an attempt to vary that by shrinking ophthalmic diagnostic gear into moveable kits and pairing them with synthetic intelligence. The corporate’s units permit frontline healthcare employees to conduct eye screenings utilizing smartphones—bringing preventive diagnostics nearer to sufferers.
Based by Anand Sivaraman, Remidio builds {hardware} and AI instruments that allow early detection of eye illnesses and, more and more, systemic well being dangers by way of retinal evaluation.
In the present day, the Bengaluru-based firm has deployed over 4,000 units globally, performed near 16 million screenings throughout 55+ international locations, and employs round 200+ folks throughout India, Singapore, and america.
From private loss to constructing a medtech firm
Sivaraman’s journey into healthcare entrepreneurship started after a private tragedy.
An engineering graduate from IIT Kharagpur, he later pursued a grasp’s, PhD, and postdoctoral analysis at MIT, specializing in the intersection of know-how and public well being.
Nonetheless, the dying of his mom from a cardiac occasion prompted him to rethink his profession trajectory.
“I misplaced my mom to a cardiac occasion, which pushed me to return to India and ask what know-how might do for public well being,” Sivaraman says.
Earlier than beginning Remidio, he labored on diagnostic applied sciences within the HIV/AIDS testing house and helped construct an organization that was ultimately acquired by American biomedical firm Beckman Coulter.
The thought for Remidio emerged throughout a dialog with an ophthalmologist that exposed a structural problem in eye care.
“I realised that just about 70% of an ophthalmologist’s time is spent figuring out sufferers who want remedy,” he says. “However most of their worth comes from the remedy itself. That’s once we began asking—can the identification step occur outdoors the clinic?”
Miniaturising eye diagnostics
Remidio’s reply was to reimagine ophthalmic gear in moveable kind.
The corporate has developed smartphone-based diagnostic units with customized optics able to capturing detailed retinal pictures. These pictures are then analysed utilizing AI algorithms to detect situations akin to diabetic retinopathy, glaucoma, and macular degeneration.
“All of the units you usually see inside an ophthalmology clinic have primarily been miniaturised,” Sivaraman explains. “They match right into a small bag and can be utilized by healthcare employees as an alternative of specialists.”
The units are already used throughout about 250 public well being centres in Kerala, enabling screenings nearer to the place sufferers reside.
In response to the corporate, the units are designed to be inexpensive for large-scale screening programmes and price roughly 15% lower than typical ophthalmic diagnostic gear in India.
Remidio’s product portfolio is broadly divided into two {hardware} classes. The Insta vary focuses on moveable, point-of-care diagnostic units designed for screening outdoors conventional clinics, together with handheld fundus cameras, moveable slit lamps, autorefractors, and different compact ophthalmic instruments utilized in main well being centres and neighborhood screening programmes.
The Pristine vary, alternatively, is constructed for specialist scientific settings and contains superior imaging techniques akin to widefield fundus cameras, multimodal eye evaluation platforms, optical biometers, and neonatal retinal imaging units utilized in hospitals.
Supporting each {hardware} traces is the corporate’s MediosHI AI platform, which supplies diagnostic algorithms for situations akin to diabetic retinopathy, glaucoma, age-related macular degeneration, and retinopathy of prematurity. The platform is complemented by Remidio Join, a software program layer that allows teleconsultation and affected person information administration.
AI that works with out the cloud
Past {hardware}, Remidio has invested closely in synthetic intelligence that runs straight on units.
Round 2018–2019, the corporate started growing edge AI fashions able to analysing retinal pictures with out counting on cloud GPUs.
“As a substitute of relying on cloud infrastructure, we requested whether or not AI might run straight on the gadget,” Sivaraman says.
This method permits screenings to occur even in areas with restricted web connectivity—an vital benefit in rural and low-resource settings.
Remidio’s AI instruments have undergone scientific validation and have been supported by greater than 90 peer-reviewed analysis publications, together with research in medical journals.
The corporate has additionally secured regulatory approvals throughout a number of areas, together with EU MDR certification in Europe and approvals from India’s Central Medicine Customary Management Organisation.
Utilizing the attention to detect systemic illnesses
Whereas Remidio started with ophthalmology, its know-how is now increasing into preventive well being.
The retina presents a novel view of the physique’s microvascular system, making it a possible window into broader well being situations.
The corporate is growing AI fashions that analyse retinal biomarkers to establish dangers related to heart problems, continual kidney illness, and maternal well being situations akin to preeclampsia.
“The retina is without doubt one of the few locations the place you’ll be able to non-invasively observe microvascular circulation,” Sivaraman says. “That opens the potential for detecting broader well being dangers by way of the attention.”
Scale and market presence
Remidio presently operates throughout India, Southeast Asia, america, and components of Europe, serving public well being programmes, hospitals, and insurance-driven healthcare techniques.
The corporate expects to generate Rs 80-85 crore in income this yr, with about 60% coming from India and the remaining 40% from worldwide markets.
Its units are utilized by establishments together with Aravind Eye Care System, Narayana Nethralaya, L V Prasad Eye Institute, Dr. Mohan’s Diabetes Specialities Centre.
In america, the corporate works with insurance-backed healthcare fashions the place preventive screenings could be performed at dwelling.
The dimensions of Remidio’s screening programmes has additionally revealed the extent of undiagnosed illness.
In response to the corporate, practically 99% of the instances recognized by way of its screening initiatives had not been beforehand identified.
That statistic underscores the significance of increasing entry to preventive diagnostics.
“With solely round 15,000 ophthalmologists serving a inhabitants of greater than a billion folks, relying solely on clinics won’t ever attain everybody who wants screening,” Sivaraman says.
Constructing deep-tech merchandise from India
Growing precision medical {hardware} in India was not straightforward when Remidio started its journey round 2009–2010.
“At the moment, there wasn’t actually an ecosystem for designing optical techniques and electronics regionally,” Sivaraman says.
The workforce needed to construct experience from scratch whereas navigating advanced regulatory pathways.
Nonetheless, he believes these constraints in the end formed the corporate’s method to innovation.
“India forces you to construct options inside constraints,” he says. “These constraints usually result in improvements that may scale globally.”
Trying forward
Remidio now plans to broaden its public well being screening mannequin past Kerala to different Indian states, whereas strengthening its presence in worldwide markets, notably in Europe and the US.
As its AI capabilities broaden, the corporate sees eye screening evolving right into a broader gateway for preventive healthcare.
“For us, the aim is straightforward,” Sivaraman says. “For those who can detect illness early, you’ll be able to stop blindness and enhance long-term well being outcomes.”
Elevate your perspective with NextTech Information, the place innovation meets perception.
Uncover the newest breakthroughs, get unique updates, and join with a worldwide community of future-focused thinkers.
Unlock tomorrow’s developments right now: learn extra, subscribe to our publication, and develop into a part of the NextTech neighborhood at NextTech-news.com
